Revolution Medicines, Inc. (RVMD) is highlighted as one of the oversold NASDAQ stocks to buy. A Goldman Sachs analyst initiated a Buy rating with a $65 price target on July 15, citing promising clinical developments and precision oncology focus. The company’s lead asset, daraxonrasib, is undergoing advanced clinical trials for RAS-addicted cancers like PDAC and NSCLC. Revolution Medicines is a clinical-stage precision oncology company developing novel targeted therapies.

Read more at Yahoo Finance: Revolution Medicines (RVMD) Gets Initiated With a New Buy Rating at Goldman Sachs